Bristol-Myers Squibb Company Ce logo

Bristol-Myers Squibb Company Ce (CELG.RI)

Market Closed
11 Aug, 20:00
NYSE NYSE
$
0. 09
-0.01
-7.7228%
$
816.4M Market Cap
- P/E Ratio
- Div Yield
8,914 Volume
- Eps
$ 0.1
Previous Close
Add Transaction
Day Range
0.09 0.1
Year Range
0.02 0.27
Want to track CELG.RI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CELG.RI closed today lower at $0.09, a decrease of -7.7228% from yesterday's close, completing a monthly decrease of -2.8154% or $0. Over the past 12 months, CELG.RI stock gained 29.4444%.
CELG.RI is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.

CELG.RI Chart

People also search for

Inspire Medical Systems, Inc.
$ 59.13
-0.9879%
Ardent Health Partners Inc.
$ 10.97
-0.8137%
AGL
Agilon Health Inc.
$ 86.39
-10.7357%
CONMED Corporation
$ 49.58
+0.2426%
AMN
Amn Healthcare Services Inc.
$ 33.11
-9.5355%

Bristol-Myers Squibb Company Ce (CELG.RI) FAQ

What is the stock price today?

The current price is $0.09.

On which exchange is it traded?

Bristol-Myers Squibb Company Ce is listed on NYSE.

What is its stock symbol?

The ticker symbol is CELG.RI.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 816.4M.

Has Bristol-Myers Squibb Company Ce ever had a stock split?

No, there has never been a stock split.

Bristol-Myers Squibb Company Ce Profile

Pharmaceuticals Industry
Healthcare Sector
Christopher S. Boerner CEO
NYSE Exchange
- ISIN
US Country
34,100 Employees
11 Mar 2024 Last Dividend
- Last Split
- IPO Date
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.

Contact Information

Address: Route 206 & Province Line Road
Phone: +1 609 252 4000